期刊文献+

TopoⅡ及Ki67在基底细胞样乳腺癌中的表达及意义 被引量:1

Expression and clinical significance of ToPo Ⅱ and Ki67 Protein in Basal-like breast carcinoma
下载PDF
导出
摘要 目的研究Ki67和TopoⅡ蛋白在基底细胞样乳腺癌中的表达意义。方法收集我院收治的浸润性乳腺癌标本,筛选出基底细胞样型乳腺癌(BLBC组)及83例非基底细胞样乳腺癌(非BLBC组)。用免疫组化S-P法染色检测TopoⅡ及Ki67在不同组织中的表达。结果Ki67蛋白在四种乳腺组织的阳性表达率差异有极显著性(X^2=18.36,(P=0.001),非BLBC组与BLBC组的Ki67蛋白表达差异有显著性,BLBC组的Ki67蛋白表达率水平最高。TopoⅡ表达与临床病理分期有密切关系,在BLBC组中肿瘤组织学分级越高,TopoⅡ蛋白表达越强(P〈0.05l非BLBC组中TopoII在Ⅱ级中阳性表达率最高。进一步进行Spearman等级相关分析,r=0.346,P=0.004,说明两种蛋白表达存在显著正相关性。结论Ki67蛋白在BLBC组、非BLBC组中的表达与组织学分级存在密切关系。TopoⅡ蛋白在BLBC组、非BLBC组中的表达与组织学分级、TNM分期存在密切关系。Ki67与TopoⅡ蛋白在BLBC组中表达显著高于非BLBC组。BLBC组中的Ki67与TopoⅡ蛋白表达存在着显著的正相关性。 Objective To study the expression and clinical significance of Ki67 protein and TOPOⅡ protein in basal-like breast carcinoma (BLBC). Methods Invasive breast cancer specimens were selected in the Maternal and Child Service Center. 22 cases were selected as BLBC group. And 83 cases of non-BLBC (NBLBC) were randomly selected as NBLBC group. All of samples used SP immunohistochemical method to detect the express of Topo-Ⅱ and Ki67 in different groups. Results The Ki67 protein' s positive expression rate in four breast tissue was ( X^2=18.36, P=-0.001 ), NBLBC group' s Ki67 protein had statistically difference with the BLBC group, showing that the BLBC group Ki67 protein expression rate level was the highest. Topo Ⅱ expression had close correlation with clinical pathologic stage. The result showed that in BLBC group, the higher the tumor histological grade, the higher the Topo Ⅱ protein expression( P〈 0.05 and Topo Ⅱ positive rate of NBLBC group expressed highest in level Ⅱ. Further with Spearman rank correlation analysis (r =0.346, P=-0.004) showed significant positive correlation of the two proteins. Conclusion There was close relationship between Ki67 protein expression and histologic classification in BLBC and NBLBC groups. Topo Ⅱ expressed close correlation with histologic classification and TNM classification in BLBC and NBLBC groups. The express of Ki67 and Topo Ⅱ in BLBC is significantly higher than those in NBLBC. The express of Ki67 and Topo Ⅱ have positive correlation in BLBC.
出处 《国际医药卫生导报》 2012年第10期1406-1410,共5页 International Medicine and Health Guidance News
关键词 TopoⅡ KI67 基底细胞样乳腺癌 Ki67 TOPO Ⅱ Basal-like breast carcinoma
  • 相关文献

参考文献6

二级参考文献65

  • 1陆军,陈运立,徐锡金,霍霞,许建衡.PTEN基因蛋白在乳腺癌组织中的表达及其临床意义[J].汕头大学医学院学报,2004,17(3):136-139. 被引量:6
  • 2王萍玲,胡丽娜,邓凯贤,张君,宋文鑫.RNA干扰沉默mdrl基因联合阿霉素对卵巢癌耐药细胞株SKOV_3/ADM增殖的抑制作用[J].重庆医科大学学报,2005,30(2):232-235. 被引量:7
  • 3Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Iht J Cancer, 1983,31 (1):13-20.
  • 4Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms [J]. J Pathol, 1990, 162(4): 285-294.
  • 5Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53expression in anal cancer precursor lesions [J]. Anticancer Res,2003, 23 (3C): 2995-2999.
  • 6Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations [J]. Head Neck,2003,25(4): 280-288.
  • 7Tut VM, Braithwaite AL, Angus B, et al. Gyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53,wafl, pRb and Ki67 [J]. Br J Gancer,2001, 84(2): 270-275.
  • 8Bhatavdekar JM, Patel DD, Shah NG,et al. Prognostic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis [J] . Ann Surg Oncol,2000, 7 (4): 305-311.
  • 9Vincent-Salomon A, Rousseau A, Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy [J]. Eur J Cancer,2004(40): 1502-1508.
  • 10Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation [J]. Hum Pathol,2002,33(9): 863-870.

共引文献159

同被引文献12

  • 1王蓓,傅健飞,吕晓皑.74例三阴性乳腺癌临床特征及预后分析[J].肿瘤学杂志,2009,15(11):1005-1008. 被引量:6
  • 2Li CY,Zhang S,Zhang XB. Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients:a retrospective study[J].Asian Pac J Cancer Prey,2013,(6):3779-3784.
  • 3Iwase H,Kurebayashi J,Tsuda H. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society[J].{H}Breast Cancer,2010,(2):118-124.
  • 4Wasuthit Y,Kongdan Y,Suvikapakornkul R. Predictive factors of axillary lymph node metastasis in breast cancer[J].{H}Journal of the Medical Association of Thailand,2011,(1):65-70.
  • 5Kennecke H,Yerushalmi R,Woods R. Metastatic behavior of breast cancer subtypes[J].{H}Journal of Clinical Oncology,2010,(20):3271-3277.
  • 6Rody A,Kam T,Ruckhaberle E. Gene expression of topoisomerase Ⅱ alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer[J].{H}Breast Cancer Research and Treatment,2009,(3):457-466.
  • 7韩晓蓉,郜红艺,王颀,张安秦,许娟,李文萍,朱彩霞,何秋苑.三阴性乳腺癌的临床病理特点(附35例报告)[J].中华乳腺病杂志(电子版),2009,3(1):11-13. 被引量:11
  • 8陈晓耕,林志武,柳燕,林镇和.三阴性乳腺癌的临床病理特点及预后因素分析[J].福建医科大学学报,2009,43(2):172-174. 被引量:4
  • 9黄关立,郭贵龙,张筱骅.三阴性乳腺癌的临床病理特征及生存分析[J].实用医学杂志,2010,26(17):3126-3129. 被引量:8
  • 10祝玉祥,章佳新,邵稳喜,何春兰,诸林海,符德元.ki67在三阴性乳腺癌组织中的表达及意义[J].中国现代普通外科进展,2010,13(9):679-680. 被引量:12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部